ProShare Advisors
FULC icon

ProShare Advisors’s Fulcrum Therapeutics FULC Stock Holding History

ProShare Advisors’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,656
Closed -$89.4K – 1955
2026
Q1 		$89.4K Buy
11,656
+1,397
+14% +$13K ﹤0.01% 1720
2025
Q4 		$116K Buy
+10,259
New +$104K ﹤0.01% 1844
2025
Q3 		– Sell
-10,951
Closed -$75.3K – 2055
2025
Q2 		$75.3K Sell
10,951
-706
-6% -$3.78K ﹤0.01% 1925
2025
Q1 		$33.6K Sell
11,657
-5,818
-33% -$21.4K ﹤0.01% 1996
2024
Q4 		$82.1K Buy
17,475
+2,065
+13% +$7.62K ﹤0.01% 2107
2024
Q3 		$55K Buy
+15,410
New +$114K ﹤0.01% 1967
2023
Q2 		– Sell
-10,347
Closed -$29.5K – 1869
2023
Q1 		$29.5K Buy
+10,347
New +$92.7K ﹤0.01% 1714
2022
Q2 		– Sell
-9,351
Closed -$221K – 1918
2022
Q1 		$221K Sell
9,351
-2,361
-20% -$33.4K ﹤0.01% 1822
2021
Q4 		$208K Sell
11,712
-311
-3% -$6.16K ﹤0.01% 2009
2021
Q3 		$339K Buy
12,023
+404
+3% +$7.66K ﹤0.01% 1459
2021
Q2 		$122K Buy
+11,619
New +$117K ﹤0.01% 2264

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ProShare Advisors's FULC Position: Q2 2026 in Review

ProShare Advisors sold out of Fulcrum Therapeutics (FULC) in Q2 2026, closing a stake of 11,656 shares — an estimated $89.4K sold.

ProShare Advisors first reported a position in FULC in Q2 2021 and held it in 11 quarters. The position peaked at $339K in Q3 2021. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • ProShare Advisors reported no remaining Fulcrum Therapeutics position as of Q2 2026 after selling out during the quarter.
  • ProShare Advisors sold 11,656 Fulcrum Therapeutics shares in Q2 2026, an estimated $89.4K.
  • ProShare Advisors first reported a position in Fulcrum Therapeutics in Q2 2021 and held it in 11 quarters.
  • ProShare Advisors's Fulcrum Therapeutics position peaked at $339K in Q3 2021.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.